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Menin binds to the N terminus of the chromatin-remodeling histone methyltransferase MLL and is essential
for the transforming activity of at least several oncogenic MLL fusion proteins. In this issue, Yokoyama and
Cleary (2008) show that menin’s essential, and perhaps only, contribution to leukemia is to tether a third pro-
tein, LEDGF—a chromatin-associated protein implicated in leukemia and several other disease states—to
MLL. Thus, this study identifies a new, critical player in leukemias caused by MLL fusion proteins and defines
the biochemical function of menin in the MLL complex.The myeloid/lymphoid or mixed-lineage
leukemia (MLL) gene is targeted by at
least 50 different chromosomal trans-
locations in leukemias with a particularly
poor prognosis (Krivtsov and Armstrong,
2007). The translocations result in the pro-
duction of chimeric proteins, all of which
contain the N-terminal portion of MLL
fused with a large assortment of partners
that seem to contribute either a transacti-
vation or oligomerization domain to the
oncogenic fusion protein. MLL is a very
large nuclear protein that is homologous
to Drosophila trithorax and functions to
maintain gene expression during devel-
opment. It contains at least five con-
served domains, including AT hooks that
can mediate DNA binding and a SET do-
main that can methylate lysine 4 on his-
tone H3 tails (a positive transcriptional
epigenetic mark).
MLL interacts with a large number of
proteins. Yokoyama, Cleary, and col-
leagues previously purified an MLL com-
plex containing eight polypeptides
including several members of a Set1
methyltransferase complex as well as
a ubiquitously expressed protein called
menin (Yokoyama et al., 2004). In a recip-
rocal experiment, the MLL homolog MLL2
was immunoprecipitated from 293T cells
using antibodies against menin (Hughes
et al., 2004). Menin is a nuclear protein
whose loss or inactivation causes multiple
endocrine neoplasia type 1 (MEN1, OMIM
121100), a syndrome characterized by
a triad of tumors of parathyroid, entero-
pancreatic endocrine, and anterior pitui-
tary gland origin (Chandrasekharappa
and Teh, 2003). Somatic MEN1 mutations
and loss of heterozygosity have also been
found in a variety of sporadic tumors of
endocrine and nonendocrine origin. Me-
nin binds with high affinity to a conserved
sequence located at the extreme N termi-
nus of MLL that is retained in all onco-
genic MLL fusion proteins (Caslini et al.,
2007; Yokoyama et al., 2005). A small de-
letion removing the menin binding site in
the MLL-ENL, MLL-GAS7, MLL-AF10, or
MLL-AF9 oncogenic fusion proteins de-
stroys their transforming activity (Caslini
et al., 2007; Yokoyama et al., 2005). Sim-
ilarly, loss of menin obliterates the ability
of multiple MLL fusion proteins to sustain
transformation of hematopoietic cells,
establishing the MLL/menin duo as an
essential contributor to MLL oncoprotein-
mediated leukemogenesis (Yokoyama
et al., 2005). However, menin does not
contain any known protein domains, and
it has been shown to interact with multiple
nuclear proteins including histone methyl-
transferases, histone deacetylases, and
various transcription factors. Thus, the
exact molecular contribution of menin to
endogenous MLL and MLL fusion protein
activity is poorly understood.
In a study in this issue of Cancer Cell,
Yokoyama and Cleary (2008) purified
MLL-interacting proteins from cells over-
expressing tagged versions of both MLL
and menin, with the notion that more
weakly interacting proteins might be iden-
tified by this strategy. One of the proteins
they copurified was LEDGF (lens epithe-
lium-derived growth factor), a protein
previously implicated in cancer, autoim-
munity, and AIDS (Engelman and Chere-
panov, 2008). LEDGF is also directly
involved in leukemia through transloca-
tion-induced fusion to the NUP98 protein
(Ahuja et al., 2000). LEDGF is a member
of the hepatoma-derived growth factor-
related family of proteins. It appears to
be involved in a number of transcriptional
processes—it was found associated with
RNA polymerase II (RNA pol II), and it reg-
ulates stress-induced genes (Shinohara
et al., 2002). LEDGF also binds tightly to
the HIV-1 integrase and is thought to
play a major role in tethering the HIV-1 pre-
integration complex to active chromatin
through a PWWP domain and AT hooks
located in the N-terminal half of the pro-
tein (Engelman and Cherepanov, 2008).
The PWWP domain is conserved in other
chromatin-binding proteins involved in
DNA repair, methylation, and transcription
and has been shown to targetDNA methyl-
transferases to chromatin (Chen et al.,
2004; Ge et al., 2004).
The authors demonstrate in multiple
ways that MLL, menin, and LEDGF are
a threesome. Both LEDGF and menin
bind MLL via nonoverlapping sites, and
the interaction of LEDGF with MLL re-
quires menin. All three proteins occupy
target genes (HOXA, MEIS1, and CDKI)
that have been implicated in MLL onco-
protein-mediated disease and presum-
ably work together to upregulate the
expression of those genes.
Yokoyama and Cleary (2008) specu-
lated that menin’s role in this triad is to
tether MLL to LEDGF and that LEDGF in
turn directs the complex to chromatin via
its PWWP domain (Yokoyama and Cleary,
2008). In an elegant series of experiments,
they provide compelling evidence for this
model by showing that MLL’s depen-
dence on menin and LEDGF can be en-
tirely circumvented by simply substituting
the menin binding site in an MLL oncopro-
tein (MLL-ENL) with the PWWP domain
from LEDGF (Figure 1). This modifiedCancer Cell 14, July 2008 ª2008 Elsevier Inc. 3
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PreviewsFigure 1. Multiple Lines of Evidence Demonstrate that Menin’s Role Is to Tether LEDGF to
MLL
Conditional deletion of menin, knockdown of LEDGF, and mutations that disrupt binding of LEDGF to ei-
ther MLL or menin all impair the MLL-ENL fusion protein’s transforming activity and constitutive expres-
sion of the MLL target Hoxa9. Fusion of LEDGF’s chromatin-binding PWWP domain to MLL supplants
menin activity.PWWP-domain-containing MLL-ENL
fusion protein, now incapable of binding
either menin (because its binding site
is missing) or LEDGF (whose binding to
MLL requires menin), can perform func-
tions that normally require all three pro-
teins. For example, PWWP-MLL-ENL
can occupy the Hoxa9 locus (a well-
known MLL target gene), upregulate the
expression of Hoxa9, and, most impor-
tantly, transform myeloid lineage cells
and induce leukemia in mice with the
same latency as the unmodified MLL-ENL
protein. To further drive this point home,
the authors show that PWWP-MLL-ENL
(but not MLL-ENL) is no longer dependent
on menin to maintain the transformation
of myeloid progenitors. They also show
that knocking down LEDGF reduces
both the clonogenic potential of MLL-
ENL transformed cells and Hoxa9 expres-
sion. Finally, the authors examined the
ability of mutant menin proteins found in
MEN1 patients to bind MLL and LEDGF
and to partner with MLL fusion proteins
in leukemia. More than 300 different muta-
tions, including missense and in-frame
deletions, have been found throughout
the length of the MEN1 gene in various
tumors (Chandrasekharappa and Teh,
2003). Yokoyama and Cleary found that
some mutated menin proteins retain their4 Cancer Cell 14, July 2008 ª2008 Elsevier Inc.association with MLL but cannot bind
LEDGF and cannot cooperate with MLL
fusion proteins in leukemia. Therefore,
menin’s liaison with LEDGF is essential
for the oncogenic activity of MLL fusion
proteins, and potentially for its tumor sup-
pressor activity in MEN1.
In summary, Yokoyama and Cleary
(2008) demonstrate a key role for LEDGF
in MLL’s leukemic activity and in addition
show that menin’s only job is to tether
MLL to LEDGF. These results raise sev-
eral interesting and important questions.
For example, do all MLL fusion proteins
require LEDGF? The requirement for
LEDGF was demonstrated for MLL-ENL
and MLL-AF10, both of which contain
MLL fused to the transactivation domains
of putative DNA-binding proteins. But
MLL can also be fused to proteins with
oligomerization domains, to septins, and
to histone acetyltransferases (Krivtsov
and Armstrong, 2007). Whether these
other types of MLL fusion proteins trans-
form by the same mechanism as MLL-
ENL and MLL-AF10, and whether they
also require LEDGF, is unknown. Global
chromatin immunoprecipitation studies
showed that MLL occupies up to 90% of
the sites occupied by RNA pol II. Is
LEDGF co-occupying all of these sites?
If not, what is the functional outcome of
LEDGF occupancy? LEDGF is variously
thought to influence the efficiency of
HIV-1 integration and target site selection.
Does LEDGF affect the efficiency of MLL
binding or activity? Does it bind chromatin
cooperatively with MLL (or for that matter,
can MLL occupy chromatin in the ab-
sence of LEDGF)? And is the MLL/
menin/LEDGF threesome the final story,
or is there a poly family of MLL-associated
proteins, all of which are essential for
MLL’s function in development and
leukemia? The answers to these and other
questions will undoubtedly shed light on
the epigenetic regulation of gene expres-
sion by MLL and its oncogenic derivatives
and will hopefully yield much-needed tar-
gets for treating the difficult MLL fusion
protein leukemias.
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The acquisition of a fully malignant phenotype is limited by several barriers, including cellular senescence and
the requirement to undergo an epithelial-mesenchymal transition (EMT). Deregulation of these processes is
believed to occur by largely independent events. In this issue of Cancer Cell, Ansieau et al. (2008) challenge
this view.
Tissues often contain several small and
inconspicuous neoplastic lesions, which
rarely progress to full malignancy. It is be-
lieved that multiple factors underlie this
phenomenon. These include apoptosis,
the necessity to acquire invasive compe-
tence, and the activation of a cellular
senescence program. The last of these
is receiving increased attention, moving
from being a phenomenon seen exclu-
sively in cultured cells to one constituting
a critical tumor suppression function in
vivo. It can be triggered by telomere
malfunction or unscheduled activation of
oncogenic signaling (Prieur and Peeper,
2008). Cellular (oncogene-induced) se-
nescence is characterized by a largely ir-
reversible cell-cycle arrest, often a typical
flattened cell morphology, and induction
of a tumor suppressor network.
Another factor proposed to limit pro-
gression of epithelial tumors is the re-
quirement to undergo epithelial-mesen-
chymal transition (EMT). While important
for embryonic development, EMT is often
adopted by cancer cells, endowing them
with a migratory and/or invasive pheno-
type. It is characterized by decreased
cell adhesion, which is usually accompa-
nied by the downregulation of E-cadherin.
This important epithelial adhesion protein
is regulated by several transcription fac-
tors, including Twist, Snail, and Zeb1.
Although these tumor-restricting pro-
cesses are generally seen as largely inde-
pendent traits, Ansieau et al. (2008) report
that, in fact, they may not be distinctly
autonomous as previously thought. The
authors asked whether Twist1 (overex-
pression of which is linked to breast can-
cer infiltration; Yang et al. [2004]) and
its close cousin Twist2 are activated in
cancer. To address this, they analyzed
MMTV-ErbB2-driven murine mammary
tumors, where TWIST2 levels were in-
creased in the majority of these lesions.
When extending this study to human
breast carcinomas, the authors observed
instead that TWIST1 was upregulated in
half of the cases.
The notion that Twist1 may play a rela-
tively more important role in human breast
cancer was supported when Twist pro-
teins were depleted from T47D human
breast cancer cells harboring multiple
copies of ERBB2. The authors observed
that only TWIST1 knockdown resulted in
a moderate increase in senescence-asso-
ciated b-galactosidase activity (SA-b-gal,
a commonly used marker of senescence).
This was accompanied by a modest in-
crease in the number of cells that actually
underwent cell-cycle arrest, which may be
explained by assuming that the genetic
wiring implementing senescence-associ-
ated proliferative arrest in these cancer
cells is disrupted. In human RPMI 7951
melanoma cells harboring a mutant
BRAFE600 oncoprotein, codepletion of
the two Twist proteins resulted in a similar
response. An interesting question promp-
ted by these observations is whether in the
same setting, Twist is required for the in-
vasive and metastatic capacities of these
cells. Previous work has shown this to be
the case within the context of murine
breast tumor cells (Yang et al., 2004).
A connection between Twist, senes-
cence, and the cell-cycle machinery was
initially suggested almost a decade ago
(Maestro et al., 1999). Twist1 and Twist2
(also called Dermo1) were identified in
a screen for genes antagonizing Myc-in-
duced apoptosis. While Twist1 reversed
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